<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512846</url>
  </required_header>
  <id_info>
    <org_study_id>large HCC with/without TACE</org_study_id>
    <nct_id>NCT04512846</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy in SBRT of Large HCC With or Without TACE</brief_title>
  <official_title>Comparison of Efficacy in Stereotactic Body Radiation Therapy (SBRT) of Large Hepatocellular Carcinoma (5-10 cm) With or Without Transcatheter Arterial Chemoembolization (TACE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing 302 Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma&#xD;
      participants (5-10cm) who receive stereotactic body radiation therapy with or without&#xD;
      transcatheter arterial chemoembolization.The investigators will optimize the combined&#xD;
      treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall&#xD;
      survival rates, progression-free survival rates and local control and adverse reaction&#xD;
      occurrence rates in the two groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 36 months</time_frame>
    <description>OS is calculated starting from the date of SBRT to the date of the final follow-up or demise of the patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival time</measure>
    <time_frame>From date of randomization until the date of disease progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <description>PFS is estimated starting from the date of SBRT to the date of disease progression or patient death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local control time</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <description>LC is defined starting from the date of SBRT to the date of treated-lesion progression or patient death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiation-induced liver injury rates</measure>
    <time_frame>From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reaction</measure>
    <time_frame>From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Large HCC Patients</condition>
  <condition>Stereotactic Body Radiation Therapy</condition>
  <condition>Transcatheter Arterial Chemoembolization</condition>
  <arm_group>
    <arm_group_label>CK-SBRT with TACE group</arm_group_label>
    <description>The hepatocellular carcinoma patients (5-10cm）who received SBRT with TACE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CK-SBRT group</arm_group_label>
    <description>The hepatocellular carcinoma patients (5-10cm）who received SBRT alone.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The large HCC patients who receive SBRT with or without TACE.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the&#xD;
             international guidelines for the management of HCC or by pathology&#xD;
&#xD;
          -  single lesion and longest tumor diameter were 5-10cm;&#xD;
&#xD;
          -  CP-A or B classification;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) score 0-1;&#xD;
&#xD;
          -  distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are&#xD;
             more than 5 mm&#xD;
&#xD;
          -  unsuitable for other therapies, such as patients with heart disease, uncontrolled&#xD;
             diabetes, uncontrolled hypertension, etc.&#xD;
&#xD;
          -  rejecting other therapies such as resection, liver transplantation, etc.&#xD;
&#xD;
          -  platelet count≥50 × 109/L, white blood count≥1.5 × 109/L;&#xD;
&#xD;
          -  patients infected with hepatitis B virus who are treated with adefovir or entecavir;&#xD;
             patients infected with hepatitis C virus whose HCV DNA are negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  tumor thrombus;&#xD;
&#xD;
          -  lymph node involvement;&#xD;
&#xD;
          -  extrahepatic metastasis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jing Sun</last_name>
    <phone>+8613718681094</phone>
    <email>519299998@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xuezhang Duan</last_name>
    <phone>+8613621386161</phone>
    <email>duanxuezhang2006@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing 302 hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Sun</last_name>
      <phone>+8613718681094</phone>
      <email>519299998@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao YC, Tang MY, Jiang HY, Lian ZP, Hou EC, Liang P. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma &gt;5 cm. BMC Cancer. 2016 Nov 3;16(1):834.</citation>
    <PMID>27809890</PMID>
  </results_reference>
  <results_reference>
    <citation>Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, Cheung TT, Ng KK, Chok SH, Chan AC, Dai WC, Wong FC, Luk MY, Leung TW, Lo CM. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surg Oncol. 2019 Mar;28:228-235. doi: 10.1016/j.suronc.2019.01.006. Epub 2019 Jan 29.</citation>
    <PMID>30851906</PMID>
  </results_reference>
  <results_reference>
    <citation>Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tomé WA, Verellen D, Wang L, Yin FF. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010 Aug;37(8):4078-101. Erratum in: Med Phys. 2012 Jan;39(1):563. Dosage error in article text.</citation>
    <PMID>20879569</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CyberKnife</keyword>
  <keyword>SBRT</keyword>
  <keyword>large HCC</keyword>
  <keyword>prognosis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

